Scientific Publications & Articles


Scientific Publications

 

2012

1. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.

Jeschke U, Wiest I, Schumacher AL, Kupka M, Rack B, Stahn R, Karsten U, Mayr D, Friese K, Dian D.

Anticancer Res. 2012 May;32(5):2185-9.

PMID:22593508 [PubMed - indexed for MEDLINE]

Related citations

2. Safety and tolerance of Bacteroides xylanisolvens DSM 23964 in healthy adults.

Ulsemer P, Toutounian K, Kressel G, Schmidt J, Karsten U, Hahn A, Goletz S.

Benef Microbes. 2012 Jun 1;3(2):99-111.

PMID:22417778 [PubMed - indexed for MEDLINE]

Free Article

Related citations

3. Preliminary safety evaluation of a new Bacteroides xylanisolvens isolate.

Ulsemer P, Toutounian K, Schmidt J, Karsten U, Goletz S.

Appl Environ Microbiol. 2012 Jan;78(2):528-35. Epub 2011 Nov 18.

PMID:22101046 [PubMed - indexed for MEDLINE]

Free PMC Article

Related citations

4. Safety assessment of the commensal strain Bacteroides xylanisolvens DSM 23964.

Ulsemer P, Toutounian K, Schmidt J, Leuschner J, Karsten U, Goletz S.

Regul Toxicol Pharmacol. 2012 Mar;62(2):336-46. Epub 2011 Nov 6.

PMID:22085591 [PubMed - indexed for MEDLINE]

Related citations

 

2010

Lin,W.-M., Karsten,U., Goletz,S., Cheng,R.-C., Cao,Y.: Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells. Virchows Arch. 456: 403-409 (2010).

Fan,X.-N., Karsten,U., Goletz,S., Cao,Y.: Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol.Res.Pract. 206: 585-589 (2010).

Karsten,U., Butschak,G., Stahn,R., Goletz,S.: A novel series of anti-human glycophorin A (CD235a) antibodies defining five extra- and intracellular epitopes. Int.Immunopharmacol. 10: 1354-1360 (2010).

Lin,W.-M., Karsten,U., Goletz,S., Cheng,R.-C., Cao,Y.: Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int.J.Exp.Path. (online, 2010).

 

2009

Jeschke,U., Walzel,H., Mylonas,I., Papadopoulos,P., Shabani,N., Kuhn,C., Schulze,S., Friese,K., Karsten,U., Anz,D., Kupka,M.S.: The human endometrium expresses the glycoprotein Mucin-1 and shows positive correlation for Thomsen-Friedenreich-epitope expression and galectin-1 binding. J.Histochem.Cytochem. (2009).

Jeschke,U., Mylonas,I., Kunert-Keil,C., Stahn,R., Scholz,C., Janni,W., Kuhn,C., Schröder,E., Mayr,D., Friese,K.: Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer. Histochem.Cell Biol. 131: 283-295 (2009).

Dian,D., Janni,W., Kuhn,C., Mayr,D., Karsten,U., Mylonas,I., Friese,K., Jeschke,U.: Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Onkologie 32: 238-244 (2009).

Christensen,P.A., Danielczyk,A., Ravn,P., Larsen,M., Stahn,R., Karsten,U., Goletz,S.: Modifying antibody specificity by chain shuffling of VH/VL between antibodies with related specificities. Scand.J.Immunol. 69: 1-10 (2009).

 

2008

Larsen,M., Jensen,K.B., Christensen,P.A., Suarez,E., Paris,D., Sanz,L., Ravn,P., Sauce,D., Saas,P., Goletz,S., Alvarez-Vallina,L., Kristensen,P.: Functionally fused antibodies – a novel adjuvant fusion system. J. Immunol.Methods 31: 220-227 (2008).

Cao,Y., Merling,A., Karsten,U., Goletz,S., Punzel,M., Kraft,R., Butschak,G., Schwartz-Albiez,R.: Expression of CD175 (Tn), CD175s (sialosyl-Tn), and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int.J.Cancer 123: 89-99 (2008).

 

2007

Christensen,P.A., Danielczyk,A., Ravn,P., Stahn,R., Karsten,U., Goletz,S.: A monoclonal antibody to Lewis Y/Lewis b revealing mimicry of the histone H1 to carbohydrate structures. Scand.J.Immunol. 65: 362-367 (2007).

Ravn,P., Stahn,R., Danielczyk,A., Faulstich,D., Karsten,U., Goletz,S.: The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs. Cancer Immunol.Immunother. 56: 1345-1357 (2007).

 

2006

Butschak,G., Karsten,U., Schelhaas,U., Ott,H., Emmendörffer,A., Niemeyer,B., Helmholz,H., Goletz,S.: Detection, isolation and partial characterization of an immunostimulating glycoprotein from Rhodococcus fascians. Internat.Immunopharmacol. 6: 1441-1450 (2006).

Jeschke,U., Kuhn,C., Mylonas,I., Schulze,S., Friese,K., Mayr,D., Speer,R., Briese,V., Richter,D.-U., Haase,M., Karsten,U.: Development and characterization of monoclonal antibodies for the immunohistochemical detection of glycodelin A in decidual, endometrial and gynaecological tumour tissues. Histopathology 48: 394-406 (2006).

Danielczyk,A., Stahn,R., Faulstich,D., Löffler,A., Märten,A., Karsten,U., Goletz,S.: PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol.Immunother. 55: 1337-1347 (2006).

 

2005

Stahn,R., Goletz,S., Stahn,R., Wilmanowski,R., Wang,X., Briese,V., Friese,K., Jeschke,U.: Human chorionic gonadotropin (hCG) as inhibitor of E-selectin-mediated cell adhesion. Anticancer Res. 25: 1811-1816 (2005).

Karsten,U., von Mensdorff-Pouilly,S., Goletz,S.: What makes MUC1 a tumor antigen? Tumor Biol. 26: 217-220 (2005).

 

2004

Zeisig,R., Stahn,R., Wenzel,K., Behrens,D., Fichtner,I.: Effect of sialyl Lewis X-glycoliposomes on the inhibition of E-selectin-mediated tumour cell adhesion in vitro.Biochim.Biophys.Acta 28: 31-40 (2004).

Ravn,P., Danielczyk,A., Jensen,K.B., Kristensen,P., Christensen,P.A., Larsen,M., Karsten,U., Goletz,S.: Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen. J.Mol.Biol. 343: 985-996 (2004).

Christensen,P.A., Danielczyk,A., Stahn,R., Goletz,S.: Simple separation of DNA in antibody purification. In: Protein Expression and Purification 37: 468-471 (2004).

Karsten,U., Serttas,N., Paulsen,H., Danielczyk,A., Goletz,S.: Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1). Glycobiology 14: 681-692 (2004).

 

2003

Jeschke,U., Wang,X., Briese,V., Friese,K., Stahn,R.: Glycodelin and amniotic fluid transferrin as inhibitors of E-selectin-mediated cell adhesion. Histochem.Cell Biol. 119: 345-354 (2003).

Goletz,S., Cao,Y., Danielczyk,A., Ravn,P., Schöber,U., Karsten,U.: Thomsen-Friedenreich antigen: the “hidden” tumour antigen. Adv.Exp.Med.Biol., Vol.535, Glycobiology and Medicine (ed. Axford,J.S.), Kluwer Academic/Plenum Publishers, New York, pp.147-162 (2003).

 

2002

Goletz,S., Christensen,P.A., Kristensen,P., Blohm,D., Tomlinson,I., Winter,G., Karsten,U.: Selection of large diversities of antiidiotypic antibody fragments by phage display. J.Mol.Biol. 315: 1087-1097 (2002).

Karsten,U.: CD175 Workshop Panel report. In: Leucocyte Typing VII, ed. Mason,D., et al., Oxford University Press, Oxford, p. 201-202 (2002).

Karsten,U.: CD176 Workshop Panel report. In: Leucocyte Typing VII, ed. Mason,D., et al., Oxford University Press, Oxford, p. 202-203 (2002).

Cao,Y., Karsten,U., Schwartz-Albiez,R.: Expression of Thomsen-Friedenreich-related carbohydrate antigens on human leukaemia cells. In: Leucocyte Typing VII, ed. Mason,D., et al., Oxford University Press, Oxford, p. 204-205 (2002).

Butschak,G., Karsten,U.: Isolation and characterization of Thomsen-Friedenreich-specific antibodies from human serum. Tumor Biol. 23: 113-122 (2002).


Other Articles

 

2010

Baumeister H, Goletz S.: A Matter of Cell Line Development. In: European BioPharmaceutical Review 2010: Apr. Download

 

2009

Baumeister H, Goletz S.: Novel Glycosylation Technologies for the Development of Biosimilars and Biobetters. In: Innovations In Pharmaceutical Technology 2009: Dec. Download

 

2005

Baumeister H, Goletz S.: GlycoExpress: A novel expression system for the optimal glycosylation of biotherapeutics. In: Speciality Chemicals Magazine 2005: Vol 25.

Baumeister H, Schoeber U, Schlangstedt M, Stahn R, Goletz S.: A novel human expression system for generating glycoprotein with higher activity, fully human glycosylation, and optimised sialylation. In: BioProcessing Journal 2005: Vol 4. Download

Baumeister H, Goletz S.: Voll funktionsfähige humane dendritische Zelllinie. In: Laborwelt 2005: Vol 6. Download

 

2004

Goletz S, Baumeister H.: Opportunities with NEMOD & GLYCOTOPE. In: R&D FOCUS drugnews 2004: Vol 13.

Baumeister H.: GlycoEngineering – a Technology for Production of Glycoproteins. In: BioTOPics 2004: Vol 24. Download

Baumeister H, Goletz S.. A novel technology for the production of highly active therapeutic proteins. In: DrugPlus international 2004: Vol 03. Download

Print